Contributions to nephrology
-
Multicenter Study Clinical Trial
Plasma dia-filtration for severe sepsis.
The mortality rate in severe sepsis is 30-50%, and independent liver and renal dysfunction impacts significantly on hospital and intensive care mortality. If 4 or more organs fail, mortality is > 90%. Recently, we reported a novel plasmapheresis--plasma diafiltration (PDF)--the concept of which is plasma filtration with dialysis. ⋯ On average, 12.0 +/- 16.4 sessions (range 2-70) per patient were performed. The 28-day mortality rate was 36.4%, while the predicted death rate was 68.0 +/- 17.7%. These findings suggest that PDF is a simple modality and may become a useful strategy for treatment of patients with septic multiple organ failure.
-
Acute kidney injury (AKI) requiring dialysis occurs frequently, and its pathogenesis involves multiple pathways within which hemodynamic, inflammatory and nephrotoxic factors overlap. Several studies have tried to assess the risk factors leading to AKI, and found, among other factors, that preoperative renal dysfunction is important. Currently, it is uncertain when dialysis therapy should start. However, AKI after cardiac surgery should be treated early by continuous hemodialysis.
-
Continuous hemoperfusion therapies are now widely used in critical care, and could prove to be life-saving for patients unable to receive regular hemoperfusion treatments. Unfortunately, due to the inherent difficulties in assessing the effects of treatment upon critically ill patients, the efficacy of this modality has yet to be proven. Instead of focusing exclusively on a particular form of continuous hemoperfusion or a direct comparison between the different types available, this report provides a general overview of the studies reporting on its efficacy across a wide range of conditions. The authors conclude that continuous hemoperfusion could be beneficial in some cases, but this is highly dependent upon the particular modality used.
-
Continuous renal replacement therapy (CRRT) has been extensively used in Japan as renal support for critically ill patients managed in the ICU. In Japan, active research has also been conducted on non-renal indications for CRRT, i.e. the use of CRRT for purposes other than renal support. Various methods of blood purification have been attempted to remove inflammatory mediators, such as cytokines, in patients with severe sepsis or septic shock. ⋯ In evaluating the efficacy of CRRT for non-renal indications, it is essential to focus on patients subjected to be studied, such as severe sepsis or septic shock, and to evaluate its indication, commencement, termination of therapy and also its therapeutic effects based on analysis of blood levels of the target substances to be removed (e.g. cytokines). IL-6 blood level appears to be useful as a variable for this evaluation. It is expected that evidence endorsing the validity of these methods now being attempted in Japan will be reported near future.
-
Fluid overload may occur in patients with heart failure. Further complications may arise when cardiorenal syndromes develop and the kidneys are unable to eliminate the accumulated fluid. Diuretics represent the fist line of treatment, although in some case they may be ineffective or even dangerous for the patient. ⋯ Then, an evaluation of biomarkers of heart failure and a careful analysis of body fluid composition by bioimpedance vector analysis should be carried out to establish the level of hydration and to guide fluid removal strategies. Last but not least, an adequate extracorporeal technique should be employed to remove excess fluid. Preference should be given to continuous forms of ultrafiltration (slow continuous ultrafiltration, continuous venovenous hemofiltration); these techniques guided by a continuous monitoring of circulating blood volume allow for an adequate restoration of body fluid composition minimizing hemodynamic complications and worsening of renal function especially during episodes of acute decompensated heart failure.